PepGen said PGN-EDODM1 has advanced to the highest dose cohort in the Phase 2 FREEDOM2-DM1 study, a key step in testing the therapy for myotonic dystrophy type

PepGen said PGN-EDODM1 has advanced to the highest dose cohort in the Phase 2 FREEDOM2-DM1 study, a key step in testing the therapy for myotonic dystrophy type 1. The move follows a favorable Data Safety Monitoring Board review; efficacy and safety updates are pending.